Financial statements Medicofarma
Balance sheet data of MEDICOFARMA
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|---|---|---|---|---|---|
Total assets | 83 426 624,20 | 92 401 975,37 | 104 868 554,54 | 121 059 701,05 | 128 782 830,61 | 122 981 381,80 |
A. Fixed assets | 73 373 336,12 | 73 744 745,47 | 90 010 185,22 | 95 294 233,81 | 102 074 452,62 | 111 670 660,09 |
B. Current assets | 10 053 288,08 | 18 657 229,90 | 14 858 369,32 | 25 765 467,24 | 26 708 377,99 | 11 310 721,71 |
C. Share capital contributions (basic funds) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
D. Own shares (stocks) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Total liabilities | 83 426 624,20 | 92 401 975,37 | 104 868 554,54 | 121 059 701,05 | 128 782 830,61 | 122 981 381,80 |
A. Equity | 39 002 601,37 | 53 615 184,20 | 59 876 441,95 | 65 380 605,51 | 61 687 170,20 | 74 203 641,46 |
B. Liabilities and provisions for liabilities | 44 424 022,83 | 38 786 791,17 | 44 992 112,59 | 55 679 095,54 | 67 095 660,41 | 48 777 740,34 |
I. Long-term liabilities | 11 885 370,48 | 14 789 357,26 | 14 263 959,37 | 31 798 259,40 | 21 330 648,13 | 12 510 945,76 |
II. Short-term liabilities | 27 027 082,55 | 16 693 093,08 | 23 639 069,65 | 16 764 951,81 | 38 808 105,91 | 29 879 035,98 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.